300 related articles for article (PubMed ID: 10524564)
1. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary?
Bajnok L; Mezosi E; Nagy E; Szabo J; Sztojka I; Varga J; Galuska L; Leovey A
Thyroid; 1999 Sep; 9(9):865-9. PubMed ID: 10524564
[TBL] [Abstract][Full Text] [Related]
2. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose.
Haase A; Bähre M; Lauer I; Meller B; Richter E
Exp Clin Endocrinol Diabetes; 2000; 108(2):133-7. PubMed ID: 10826521
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
[TBL] [Abstract][Full Text] [Related]
5. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
6. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
7. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
El Refaei SM; Shawkat W
Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
[TBL] [Abstract][Full Text] [Related]
8. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
Howarth D; Epstein M; Lan L; Tan P; Booker J
Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
[TBL] [Abstract][Full Text] [Related]
9. Radiation dose to patients and relatives incident to 131I therapy.
Zanzonico PB
Thyroid; 1997 Apr; 7(2):199-204. PubMed ID: 9133684
[TBL] [Abstract][Full Text] [Related]
10. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
11. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration.
Calegaro JU; De Freitas Gomes E; Bae SH; Ulyssea R; Casulari LA
Panminerva Med; 2000 Dec; 42(4):241-5. PubMed ID: 11294085
[TBL] [Abstract][Full Text] [Related]
12. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
Alexander EK; Larsen PR
J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
[TBL] [Abstract][Full Text] [Related]
13. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome.
Catargi B; Leprat F; Guyot M; Valli N; Ducassou D; Tabarin A
Eur J Endocrinol; 1999 Aug; 141(2):117-21. PubMed ID: 10427153
[TBL] [Abstract][Full Text] [Related]
14. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
15. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G
Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
[TBL] [Abstract][Full Text] [Related]
16. [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement].
Watanabe M; Ito K; Mimura T; Ishikawa N; Ino E; Saitoh T; Tsuji H; Tsuchiya T
Kaku Igaku; 1993 Sep; 30(9):1055-62. PubMed ID: 8230826
[TBL] [Abstract][Full Text] [Related]
17. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
18. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic results of radioiodine therapy of hyperthyroid thyroid gland diseases].
Debrand-Passard A; Barzen G; Richter W; Wenzel KW; Felix R
Med Klin (Munich); 1994 Jun; 89(6):319-23. PubMed ID: 8072455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
